Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls

Atherosclerosis

Volumn 122, Issue 2, 1996, Pages 245-253

  Van De Vijver, Lucy P L ^a,b   Steyger, Roland ^a   Van Poppel, Geert ^a   Boer, Jolanda M A ^c   Kruijssen, Dick A C M ^d   Seidell, Jacob C ^c   Princen, Hans M G ^a  

^a TNO   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

Atherosclerosis; Autoantibodies; Cardiovascular diseases; LDL oxidation

Indexed keywords

AUTOANTIBODY; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK;

EID: 0029885602     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05759-5     Document Type: Article

References (36)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915.
2. Steinbrecher UP, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Rad Biol Med 1990;9:155.
3. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785.
4. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992;13:341.
5. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990;10:325.
6. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci 1989;86:1372.
7. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990;114:383.
8. Orekhov AN, Tertov VV, Kabakov AE, Adamova IY, Pokrovsky SN, Smirnov VN. Autoantibodies against modified low density lipoprotein. Arterioscl Thromb 1991;11:316.
9. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883.
10. Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E, Bellomo G. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coronary Artery Disease 1993;4:1119.
11. Craig WY, Poulin SE, Nelson CP, Ritchie RF. Elisa of IgG antibody to oxidized Low Density Lipoprotein: effects of blocking buffer and method of data expression. Clin Chem 1994;40:882.
12. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis. Arterioscl Thromb 1994;14:1892.
13. Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994;154:2605.
14. Maggi E, Marchesi F, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: A biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypert 1995;13:129.
15. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32.
16. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990;10:336.
17. Tatzber F, Rabl H, Koriska K, Erhart U, Puhl H, Waeg G, Krebs A, Esterbauer H. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991;89:203.
18. Schumacher M, Eber B, Tatzber F, Kaufman P, Esterbauer H, Klein W. LDL oxidation and coronary atherosclerosis (letter). Lancet 1992;340:123.
19. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993;23:95.
20. Verschuren WMM, Van Leer EM, Blokstra A, Seidell JC, Smit HA, Bueno de Mesquita HB, Oberman-de Boer GL, Kromhout D. Cardiovascular disease risk factors in the Netherlands. Neth J Cardiol 1993;4:205.
21. 1-Tetra-methylbenzidine as an ames test negative chromogen for horse radish peroxidase in enzyme immunoassay. J Immunoassay 1981;2:187.
22. Sullivan DR, Kruijswijk Z, West CE, Kohlmeier M, Katan MB. Determination of serum triglycerides by an accurate enzymatic method not affected by free Glycerol. Clin Chem 1985;31:1227.
23. Warnick GR, Benderson J, Albers JJ. Dextran Sulfate-Mg2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982;28:1379.
24. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of LDL-cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
25. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID. Measurement of low density lipoprotein cholesterol in serum: a status report. Clin Chem 1992;38:150.
26. Dixon WJ, (ed). BMDP Statistical software manual version 7.0, California, 1992.
27. Jialal I, Freeman DA, Grundy S. Varying susceptibility of different low density lipoproteins to oxidative modification. Arterioscl Thromb 1991;11:482.
28. Liu K, Cuddy E, Pierce GN. Oxidative status of lipoproteins in coronary disease patients. Am Heart J 1992;123:285.
29. Niki E. Antioxidants in relation to lipid peroxidation. Chem Phys Lipids 1987;44:227.
30. Packer L. Protective role of vitamin E in biological systems. Am J Clin Nutr 1991;53:S1050.
31. Princen HMG, Van Duyvenvoorde W, Buytenhek R, Van der Laarse A, Van Poppel G, Gevers Leuven JA, Van Hinsbergh VWM. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women. Arterioscler Thromb Vasc Biol 1995;15:325.
32. Reaven PD, Parthasaraty S, Grasse BJ, Miller E, Almazan F, Mattson FH, Khoo JC, Steinberg D, Witztum J. Feasibility of using an oleate-rich diet to reduce the susceptibility of low density lipoprotein to oxidative modification in humans. Am J Clin Nutr 1991;54:701.
33. Pryor WA, Hales BJ, Premovic PJ, Church DF. The radicals in cigarette tar: their nature and suggested physiological implications. Science 1983;220:425.
34. Stryker WS, Kaplan LA, Stein EA, Stampfer MJ, Sober A, Willett WC. The relation of diet, cigarette smoking, and alcohol consumption to plasma β-carotene and α-tocopherol levels. Am J Epidemiol 1988;127:283.
35. Harats D, Ben-Naim M, Dabach Y, Hollander G, Havivi E, Stein O, Stein Y. Effect of vitamin C and E supplementation on susceptibility of plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis 1990;85:47.
36. Princen HMG, Van Poppel G, Vogelezang C, Buytenhek R, Kok FJ. Supplementation with vitamin E but not β-carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. Arterioscler Thromb 1992;12:554.